reMYND

Foundation date

2002

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).

Upcoming events

Latest news

  • SeptiCyte® RAPID receives 510(k) clearance by US FDA

    Wednesday December 1st 2021

  • QbD and Inovigate launch Health to Market, a contract commercialization organization in life sciences

    Wednesday December 1st 2021

  • Dimitrios Mantzilas joins Precirix as Chief Technology Officer

    Wednesday December 1st 2021